Value of Intense Phenotyping in Heart Failure With Preserved Ejection Fraction
ConditionHeart Failure, Diastolic
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorUniversity Medical Center Groningen
About this trial
Heart failure (HF) with a left ventricular ejection fraction (LVEF) \>0.40 is a large medical problem, for which no drug or device has a recommendation in current HF guidelines. The prevalence of mortality and HF hospitalizations in HF with LVEF \>0.40 is high, but the identification of predictors for increased risk of mortality and HF hospitalizations in this patient category remains difficult. The hypothesis of this study is that the risk of all-cause mortality and HF hospitalizations can be measured by clinical factors, imaging parameters and circulating biomarkers, and that these factors can be used in a risk profile
Eligibility criteria
Qualifiers
Age >18 years
Written informed consent
HF with moderate to severe symptoms NYHA II or III
Hospitalization or emergency room visit for HF or symptom relief with diuretics
Disqualifiers
Patients unwilling or unable to sign informed consent
Patients with a pacemaker or ICD
Indication for ICD therapy according to the ESC guidelines
Life expectancy of less than one year
Trial design
Treatments tested in this trial
- Echocardiography
- 24 hour Holter monitoring
- Cardiac Magnetic Resonance Imaging
- 99mTc-HDP scan
- ECG
Treatment groups
No treatment groups listed
Sponsors and collaborators
Source ClinicalTrials.gov